{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:55:16Z","timestamp":1792698916818,"version":"4.5.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:00:00Z","timestamp":1713398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:00:00Z","timestamp":1713398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81972991"],"award-info":[{"award-number":["81972991"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Pediatr"],"DOI":"10.1007\/s00431-024-05519-1","type":"journal-article","created":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T11:01:51Z","timestamp":1713438111000},"page":"3001-3011","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":122,"title":["Challenges in the treatment of pediatric Mycoplasma pneumoniae pneumonia"],"prefix":"10.1007","volume":"183","author":[{"given":"Guodong","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Vinturache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemarie M. C.","family":"van Rossum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,18]]},"reference":[{"issue":"1","key":"5519_CR1","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/INF.0000000000000171","volume":"33","author":"TP Atkinson","year":"2014","unstructured":"Atkinson TP, Waites KB (2014) Mycoplasma pneumoniae infections in Childhood. Pediatr Infect Dis J 33(1):92\u201394","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"5519_CR2","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/00001432-200104000-00012","volume":"14","author":"MR Hammerschlag","year":"2001","unstructured":"Hammerschlag MR (2001) Mycoplasma pneumoniae infections. Curr Opin Infect Dis 14(2):181\u2013186","journal-title":"Curr Opin Infect Dis"},{"issue":"3","key":"5519_CR3","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jiac.2013.09.009","volume":"20","author":"K Izumikawa","year":"2014","unstructured":"Izumikawa K, Izumikawa K, Takazono T, Kosai K, Morinaga Y, Nakamura S, Kurihara S, Imamura Y, Miyazaki T, Tsukamoto M, Yanagihara K, Hara K, Kohno S (2014) Clinical features, risk factors and treatment of fulminant Mycoplasma pneumoniae pneumonia: a review of the Japanese literature. J Infect Chemother 20(3):181\u2013185","journal-title":"J Infect Chemother"},{"issue":"3","key":"5519_CR4","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/ppul.20374","volume":"41","author":"KY Lee","year":"2006","unstructured":"Lee KY, Lee HS, Hong JH, Lee MH, Lee JS, Burgner D, Lee BC (2006) Role of prednisolone treatment in severe Mycoplasma pneumoniae pneumonia in children. Pediatr Pulmonol 41(3):263\u2013268","journal-title":"Pediatr Pulmonol"},{"issue":"6","key":"5519_CR5","doi-asserted-by":"crossref","first-page":"635","DOI":"10.2217\/17460913.3.6.635","volume":"3","author":"KB Waites","year":"2008","unstructured":"Waites KB, Balish MF, Atkinson TP (2008) New insights into the pathogenesis and detection of Mycoplasma pneumoniae infections. Future Microbiol 3(6):635\u2013648","journal-title":"Future Microbiol"},{"issue":"5","key":"5519_CR6","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1128\/AAC.00090-09","volume":"53","author":"KB Waites","year":"2009","unstructured":"Waites KB, Crabb DM, Duffy LB (2009) Comparative in vitro susceptibilities of human mycoplasmas and ureaplasmas to a new investigational ketolide, CEM-101. Antimicrob Agents Chemother 53(5):2139\u20132141","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"5519_CR7","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.3201\/eid1908.121455","volume":"19","author":"KB Hong","year":"2013","unstructured":"Hong KB, Choi EH, Lee HJ, Lee SY, Cho EY, Choi JH, Kang HM, Lee J, Ahn YM, Kang YH, Lee JH (2013) Macrolide resistance of Mycoplasma pneumoniae, South Korea, 2000\u20132011. Emerg Infect Dis 19(8):1281\u20131284","journal-title":"Emerg Infect Dis"},{"issue":"3","key":"5519_CR8","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1093\/jac\/dks457","volume":"68","author":"N Principi","year":"2013","unstructured":"Principi N, Esposito S (2013) Macrolide-resistant Mycoplasma pneumoniae: its role in respiratory infection. J Antimicrob Chemother 68(3):506\u2013511","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"5519_CR9","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1128\/AAC.50.2.709-712.2006","volume":"50","author":"S Suzuki","year":"2006","unstructured":"Suzuki S, Yamazaki T, Narita M, Okazaki N, Suzuki I, Andoh T, Matsuoka M, Kenri T, Arakawa Y, Sasaki T (2006) Clinical evaluation of macrolide-resistant Mycoplasma pneumoniae. Antimicrob Agents Chemother 50(2):709\u2013712","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"5519_CR10","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1128\/AAC.00048-13","volume":"57","author":"Y Kawai","year":"2013","unstructured":"Kawai Y, Miyashita N, Kubo M, Akaike H, Kato A, Nishizawa Y, Saito A, Kondo E, Teranishi H, Ogita S, Tanaka T, Kawasaki K, Nakano T, Terada K, Ouchi K (2013) Therapeutic efficacy of macrolides, minocycline, and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae pneumonia in pediatric patients. Antimicrob Agents Chemother 57(5):2252\u20132258","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"5519_CR11","doi-asserted-by":"crossref","first-page":"5181","DOI":"10.1128\/AAC.00737-13","volume":"57","author":"N Miyashita","year":"2013","unstructured":"Miyashita N, Akaike H, Teranishi H, Ouchi K, Okimoto N (2013) Macrolide-resistant Mycoplasma pneumoniae pneumonia in adolescents and adults: clinical findings, drug susceptibility, and therapeutic efficacy. Antimicrob Agents Chemother 57(10):5181\u20135185","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"5519_CR12","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.idc.2009.06.013","volume":"23","author":"JM Zuckerman","year":"2009","unstructured":"Zuckerman JM, Qamar F, Bono BR (2009) Macrolides, ketolides, and glycylcyclines: azithromycin, clarithromycin, telithromycin, tigecycline. Infect Dis Clin North Am 23(4):997\u20131026 ix-x","journal-title":"Infect Dis Clin North Am"},{"key":"5519_CR13","unstructured":"Tsai TA, Tsai CK, Kuo KC, Yu HR Rational stepwise approach for Mycoplasma pneumoniae pneumonia in children. J Microbiol Immunol Infect. 2020:S1684-1182(20)30247-4."},{"issue":"12","key":"5519_CR14","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1093\/cid\/cis784","volume":"55","author":"T Okada","year":"2012","unstructured":"Okada T, Morozumi M, Tajima T, Hasegawa M, Sakata H, Ohnari S, Chiba N, Iwata S, Ubukata K (2012) Rapid effectiveness of minocycline or doxycycline against macrolide-resistant Mycoplasma pneumoniae infection in a 2011 outbreak among Japanese children. Clin Infect Dis 55(12):1642\u20131649","journal-title":"Clin Infect Dis"},{"issue":"2","key":"5519_CR15","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1128\/JCM.02840-12","volume":"51","author":"F Cardinale","year":"2013","unstructured":"Cardinale F, Chironna M, Chinellato I, Principi N, Esposito S (2013) Clinical relevance of Mycoplasma pneumoniae macrolide resistance in children. J Clin Microbiol 51(2):723\u2013724","journal-title":"J Clin Microbiol"},{"issue":"1","key":"5519_CR16","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1128\/AAC.00779-07","volume":"52","author":"M Morozumi","year":"2008","unstructured":"Morozumi M, Iwata S, Hasegawa K, Chiba N, Takayanagi R, Matsubara K, Nakayama E, Sunakawa K, Ubukata K, Acute Respiratory Diseases Study Group (2008) Increased macrolide resistance of Mycoplasma pneumoniae in pediatric patients with community-acquired pneumonia. Antimicrob Agents Chemother 52(1):348\u2013350","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"5519_CR17","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1007\/s10156-009-0715-7","volume":"15","author":"K Matsubara","year":"2009","unstructured":"Matsubara K, Morozumi M, Okada T, Matsushima T, Komiyama O, Shoji M, Ebihara T, Ubukata K, Sato Y, Akita H, Sunakawa K, Iwata S (2009) A comparative clinical study of macrolide-sensitive and macrolide-resistant Mycoplasma pneumoniae infections in pediatric patients. J Infect Chemother 15(6):380\u2013383","journal-title":"J Infect Chemother"},{"issue":"3","key":"5519_CR18","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1128\/CMR.00114-16","volume":"30","author":"KB Waites","year":"2017","unstructured":"Waites KB, Xiao L, Liu Y, Balish MF, Atkinson TP (2017) Mycoplasma pneumoniae from the respiratory tract and Beyond. Clin Microbiol Rev 30(3):747\u2013809","journal-title":"Clin Microbiol Rev"},{"issue":"12","key":"5519_CR19","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1128\/AAC.39.12.2770","volume":"39","author":"TS Lucier","year":"1995","unstructured":"Lucier TS, Heitzman K, Liu SK, Hu PC (1995) Transition mutations in the 23S rRNA of erythromycin-resistant isolates of Mycoplasma pneumoniae. Antimicrob Agents Chemother 39(12):2770\u20132773","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"5519_CR20","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1128\/CMR.17.4.697-728.2004","volume":"17","author":"KB Waites","year":"2004","unstructured":"Waites KB, Talkington DF (2004) Mycoplasma pneumoniae and its role as a human pathogen. Clin Microbiol Rev 17(4):697\u2013728","journal-title":"Clin Microbiol Rev"},{"issue":"5","key":"5519_CR21","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1128\/AAC.01684-08","volume":"53","author":"Y Liu","year":"2009","unstructured":"Liu Y, Ye X, Zhang H, Xu X, Li W, Zhu D, Wang M (2009) Antimicrobial susceptibility of Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant strains from Shanghai, China. Antimicrob Agents Chemother 53(5):2160\u20132162","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"5519_CR22","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/ppul.22851","volume":"49","author":"Z Ma","year":"2014","unstructured":"Ma Z, Zheng Y, Deng J, Ma X, Liu H (2014) Characterization of macrolide resistance of Mycoplasma pneumoniae in children in Shenzhen, China. Pediatr Pulmonol 49(7):695\u2013700","journal-title":"Pediatr Pulmonol"},{"issue":"5","key":"5519_CR23","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1128\/AAC.01563-08","volume":"53","author":"D Xin","year":"2009","unstructured":"Xin D, Mi Z, Han X, Qin L, Li J, Wei T, Chen X, Ma S, Hou A, Li G, Shi D (2009) Molecular mechanisms of macrolide resistance in clinical isolates of Mycoplasma pneumoniae from China. Antimicrob Agents Chemother 53(5):2158\u20132159","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"5519_CR24","doi-asserted-by":"crossref","first-page":"4624","DOI":"10.1128\/AAC.48.12.4624-4630.2004","volume":"48","author":"M Matsuoka","year":"2004","unstructured":"Matsuoka M, Narita M, Okazaki N, Ohya H, Yamazaki T, Ouchi K, Suzuki I, Andoh T, Kenri T, Sasaki Y, Horino A, Shintani M, Arakawa Y, Sasaki T (2004) Characterization and molecular analysis of macrolide-resistant Mycoplasma pneumoniae clinical isolates obtained in Japan. Antimicrob Agents Chemother 48(12):4624\u20134630","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"5519_CR25","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1128\/AAC.01806-13","volume":"58","author":"Y Zhou","year":"2014","unstructured":"Zhou Y, Zhang Y, Sheng Y, Zhang L, Shen Z, Chen Z (2014) More complications occur in macrolide-resistant than in macrolide-sensitive Mycoplasma pneumoniae pneumonia. Antimicrob Agents Chemother 58(2):1034\u20131038","journal-title":"Antimicrob Agents Chemother"},{"key":"5519_CR26","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1186\/1471-2334-13-591","volume":"13","author":"K Matsuda","year":"2013","unstructured":"Matsuda K, Narita M, Sera N, Maeda E, Yoshitomi H, Ohya H, Araki Y, Kakuma T, Fukuoh A, Matsumoto K (2013) Gene and cytokine profile analysis of macrolide-resistant Mycoplasma pneumoniae infection in Fukuoka, Japan. BMC Infect Dis 13:591","journal-title":"BMC Infect Dis"},{"issue":"4","key":"5519_CR27","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/crj.12379","volume":"11","author":"B Cao","year":"2017","unstructured":"Cao B, Qu JX, Yin YD, Eldere JV (2017) Overview of antimicrobial options for Mycoplasma pneumoniae pneumonia: focus on macrolide resistance. Clin Respir J 11(4):419\u2013429","journal-title":"Clin Respir J"},{"issue":"2","key":"5519_CR28","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1440-1843.2011.02102.x","volume":"17","author":"Y Kawai","year":"2012","unstructured":"Kawai Y, Miyashita N, Yamaguchi T, Saitoh A, Kondoh E, Fujimoto H, Teranishi H, Inoue M, Wakabayashi T, Akaike H, Ogita S, Kawasaki K, Terada K, Kishi F, Ouchi K (2012) Clinical efficacy of macrolide antibiotics against genetically determined macrolide-resistant Mycoplasma pneumoniae pneumonia in paediatric patients. Respirology 17(2):354\u2013362","journal-title":"Respirology"},{"issue":"3","key":"5519_CR29","doi-asserted-by":"crossref","first-page":"e0173635","DOI":"10.1371\/journal.pone.0173635","volume":"12","author":"N Ishiguro","year":"2017","unstructured":"Ishiguro N, Koseki N, Kaiho M, Ariga T, Kikuta H, Togashi T, Oba K, Morita K, Nagano N, Nakanishi M, Hara K, Hazama K, Watanabe T, Yamanaka T, Sasaki S, Furuyama H, Shibata M, Shida S, Ishizaka A, Tabata Y, Aoyagi H, Naito H, Yoshioka M, Horino A, Kenri T (2017) Hokkaido Pediatric Respiratory Infection Study Group. Therapeutic efficacy of azithromycin, clarithromycin, minocycline and tosufloxacin against macrolide-resistant and macrolide-sensitive Mycoplasma pneumoniae pneumonia in pediatric patients. PLoS ONE 12(3):e0173635","journal-title":"PLoS ONE"},{"issue":"12","key":"5519_CR30","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1097\/INF.0b013e3182a25c71","volume":"32","author":"DC Lung","year":"2013","unstructured":"Lung DC, Yip EK, Lam DS, Que TL (2013) Rapid defervescence after doxycycline treatment of macrolide-resistant Mycoplasma pneumoniae-associated community-acquired pneumonia in children. Pediatr Infect Dis J 32(12):1396\u20131399","journal-title":"Pediatr Infect Dis J"},{"issue":"9","key":"5519_CR31","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/j.clinthera.2005.09.005","volume":"27","author":"K Smith","year":"2005","unstructured":"Smith K, Leyden JJ (2005) Safety of doxycycline and minocycline: a systematic review. Clin Ther 27(9):1329\u20131342","journal-title":"Clin Ther"},{"issue":"2","key":"5519_CR32","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1177\/0009922806290026","volume":"46","author":"B Volovitz","year":"2007","unstructured":"Volovitz B, Shkap R, Amir J, Calderon S, Varsano I, Nussinovitch M (2007) Absence of tooth staining with doxycycline treatment in young children. Clin Pediatr (Phila) 46(2):121\u2013126","journal-title":"Clin Pediatr (Phila)"},{"issue":"5","key":"5519_CR33","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.jpeds.2015.02.015","volume":"166","author":"SR Todd","year":"2015","unstructured":"Todd SR, Dahlgren FS, Traeger MS, Beltr\u00e1n-Aguilar ED, Marianos DW, Hamilton C, McQuiston JH, Regan JJ (2015) No visible dental staining in children treated with doxycycline for suspected Rocky Mountain spotted fever. J Pediatr 166(5):1246\u20131251","journal-title":"J Pediatr"},{"issue":"1","key":"5519_CR34","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1542\/peds.86.1.123","volume":"86","author":"JS Abramson","year":"1990","unstructured":"Abramson JS, Givner LB (1990) Should tetracycline be contraindicated for therapy of presumed Rocky Mountain spotted fever in children less than 9 years of age? Pediatrics 86(1):123\u2013124","journal-title":"Pediatrics"},{"issue":"5","key":"5519_CR35","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S1473-3099(01)00147-5","volume":"1","author":"N Principi","year":"2001","unstructured":"Principi N, Esposito S (2001) Emerging role of Mycoplasma pneumoniae and Chlamydia pneumoniae in paediatric respiratory-tract infections. Lancet Infect Dis 1(5):334\u2013344","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"5519_CR36","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1442-200X.2010.03316.x","volume":"53","author":"S Uehara","year":"2011","unstructured":"Uehara S, Sunakawa K, Eguchi H, Ouchi K, Okada K, Kurosaki T, Suzuki H, Tsutsumi H, Haruta T, Mitsuda T, Yamazaki T (2011) Japanese guidelines for the management of respiratory infectious diseases in Children 2007 with focus on pneumonia. Pediatr Int 53(2):264\u2013276","journal-title":"Pediatr Int"},{"key":"5519_CR37","unstructured":"The Selection and Use of Essential Medicines, Report of the WHO Expert Committee (2009) Available at: http:\/\/www.who.int\/medicines\/publications\/TRS958June2010.pdf. Accessed September 14, 2010"},{"issue":"6","key":"5519_CR38","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1183\/09031936.00172510","volume":"37","author":"F Cardinale","year":"2011","unstructured":"Cardinale F, Chironna M, Dumke R, Binetti A, Daleno C, Sallustio A, Valzano A, Esposito S (2011) Macrolide-resistant Mycoplasma pneumoniae in paediatric pneumonia. Eur Respir J 37(6):1522\u20131524","journal-title":"Eur Respir J"},{"issue":"6A","key":"5519_CR39","doi-asserted-by":"crossref","first-page":"35S","DOI":"10.1016\/0002-9343(91)90308-K","volume":"91","author":"DR Patterson","year":"1991","unstructured":"Patterson DR (1991) Quinolone toxicity: methods of assessment. Am J Med 91(6A):35S\u201337S","journal-title":"Am J Med"},{"issue":"12","key":"5519_CR40","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1097\/01.inf.0000101994.25947.12","volume":"22","author":"R Grady","year":"2003","unstructured":"Grady R (2003) Safety profile of quinolone antibiotics in the pediatric population. Pediatr Infect Dis J 22(12):1128\u20131132","journal-title":"Pediatr Infect Dis J"},{"issue":"10","key":"5519_CR41","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1097\/INF.0b013e3180cbd382","volume":"26","author":"GJ Noel","year":"2007","unstructured":"Noel GJ, Bradley JS, Kauffman RE, Duffy CM, Gerbino PG, Arguedas A, Bagchi P, Balis DA, Blumer JL (2007) Comparative safety profile of levofloxacin in 2523 children with a focus on four specific musculoskeletal disorders. Pediatr Infect Dis J 26(10):879\u2013891","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"5519_CR42","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1542\/peds.2013-3636","volume":"134","author":"JS Bradley","year":"2014","unstructured":"Bradley JS, Kauffman RE, Balis DA, Duffy CM, Gerbino PG, Maldonado SD, Noel GJ (2014) Assessment of musculoskeletal toxicity 5 years after therapy with levofloxacin. Pediatrics 134(1):e146\u2013e153","journal-title":"Pediatrics"},{"issue":"2","key":"5519_CR43","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ijantimicag.2017.02.027","volume":"50","author":"M Morozumi","year":"2017","unstructured":"Morozumi M, Okada T, Tajima T, Ubukata K, Iwata S (2017) Killing kinetics of minocycline, doxycycline and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae. Int J Antimicrob Agents 50(2):255\u2013257","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"5519_CR44","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jinf.2008.06.012","volume":"57","author":"A Tamura","year":"2008","unstructured":"Tamura A, Matsubara K, Tanaka T, Nigami H, Yura K, Fukaya T (2008) Methylprednisolone pulse therapy for refractory Mycoplasma pneumoniae pneumonia in children. J Infect 57(3):223\u2013228","journal-title":"J Infect"},{"issue":"1","key":"5519_CR45","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4168\/aair.2014.6.1.22","volume":"6","author":"SY You","year":"2014","unstructured":"You SY, Jwa HJ, Yang EA, Kil HR, Lee JH (2014) Effects of Methylprednisolone Pulse Therapy on Refractory Mycoplasma pneumoniae Pneumonia in Children. Allergy Asthma Immunol Res 6(1):22\u201326","journal-title":"Allergy Asthma Immunol Res"},{"issue":"4","key":"5519_CR46","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s12519-017-0014-9","volume":"13","author":"LS Shan","year":"2017","unstructured":"Shan LS, Liu X, Kang XY, Wang F, Han XH, Shang YX (2017) Effects of methylprednisolone or immunoglobulin when added to standard treatment with intravenous azithromycin for refractory Mycoplasma pneumoniae pneumonia in children. World J Pediatr 13(4):321\u2013327","journal-title":"World J Pediatr"},{"issue":"1","key":"5519_CR47","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12879-021-05830-4","volume":"21","author":"Z Zhu","year":"2021","unstructured":"Zhu Z, Zhang T, Guo W, Ling Y, Tian J, Xu Y (2021) Clinical characteristics of refractory mycoplasma pneumoniae pneumonia in children treated with glucocorticoid pulse therapy. BMC Infect Dis 21(1):126","journal-title":"BMC Infect Dis"},{"key":"5519_CR48","doi-asserted-by":"crossref","first-page":"37037","DOI":"10.1038\/srep37037","volume":"6","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Mei S, Zhou Y, Huang M, Dong G, Chen Z (2016) Cytokines as the good predictors of refractory Mycoplasma pneumoniae pneumonia in school-aged children. Sci Rep 6:37037","journal-title":"Sci Rep"},{"issue":"4","key":"5519_CR49","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jiac.2014.01.001","volume":"20","author":"N Inamura","year":"2014","unstructured":"Inamura N, Miyashita N, Hasegawa S, Kato A, Fukuda Y, Saitoh A, Kondo E, Teranishi H, Wakabayashi T, Akaike H, Tanaka T, Ogita S, Nakano T, Terada K, Ouchi K (2014) Management of refractory Mycoplasma pneumoniae pneumonia: utility of measuring serum lactate dehydrogenase level. J Infect Chemother 20(4):270\u2013273","journal-title":"J Infect Chemother"},{"issue":"3","key":"5519_CR50","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jiac.2014.10.008","volume":"21","author":"N Miyashita","year":"2015","unstructured":"Miyashita N, Kawai Y, Inamura N, Tanaka T, Akaike H, Teranishi H, Wakabayashi T, Nakano T, Ouchi K, Okimoto N (2015) Setting a standard for the initiation of steroid therapy in refractory or severe Mycoplasma pneumoniae pneumonia in adolescents and adults. J Infect Chemother 21(3):153\u2013160","journal-title":"J Infect Chemother"},{"issue":"1","key":"5519_CR51","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4103\/0255-0857.174112","volume":"34","author":"R Chaudhry","year":"2016","unstructured":"Chaudhry R, Ghosh A, Chandolia A (2016) Pathogenesis of Mycoplasma pneumoniae: an update. Indian J Med Microbiol 34(1):7\u201316","journal-title":"Indian J Med Microbiol"},{"issue":"12","key":"5519_CR52","doi-asserted-by":"crossref","first-page":"e14417","DOI":"10.1371\/journal.pone.0014417","volume":"5","author":"JF Lai","year":"2010","unstructured":"Lai JF, Zindl CL, Duffy LB, Atkinson TP, Jung YW, van Rooijen N, Waites KB, Krause DC, Chaplin DD (2010) Critical role of macrophages and their activation via MyD88-NF\u03baB signaling in lung innate immunity to Mycoplasma pneumoniae. PLoS ONE 5(12):e14417","journal-title":"PLoS ONE"},{"key":"5519_CR53","unstructured":"Dukhinova M, Kokinos E, Kuchur P, Komissarov A, Shtro A (2020) Macrophage-derived cytokines in pneumonia: linking cellular immunology and genetics. Cytokine Growth Factor Rev. : S1359-6101(20)30229-X."},{"issue":"6","key":"5519_CR54","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1128\/CDLI.7.6.909-914.2000","volume":"7","author":"M Narita","year":"2000","unstructured":"Narita M, Tanaka H, Abe S, Yamada S, Kubota M, Togashi T (2000) Close association between pulmonary disease manifestation in Mycoplasma pneumoniae infection and enhanced local production of interleukin-18 in the lung, independent of gamma interferon. Clin Diagn Lab Immunol 7(6):909\u2013914","journal-title":"Clin Diagn Lab Immunol"},{"issue":"2","key":"5519_CR55","doi-asserted-by":"crossref","first-page":"E31","DOI":"10.1086\/318446","volume":"32","author":"M Socan","year":"2001","unstructured":"Socan M, Ravnik I, Bencina D, Dovc P, Zakotnik B, Jazbec J (2001) Neurological symptoms in patients whose cerebrospinal fluid is culture- and\/or polymerase chain reaction-positive for Mycoplasma pneumoniae. Clin Infect Dis 32(2):E31\u2013E35","journal-title":"Clin Infect Dis"},{"issue":"1","key":"5519_CR56","doi-asserted-by":"crossref","first-page":"E16","DOI":"10.1086\/338158","volume":"34","author":"M Szymanski","year":"2002","unstructured":"Szymanski M, Petric M, Saunders FE, Tellier R (2002) Mycoplasma pneumoniae pericarditis demonstrated by polymerase chain reaction and electron microscopy. Clin Infect Dis 34(1):E16\u2013E17","journal-title":"Clin Infect Dis"},{"issue":"10","key":"5519_CR57","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.4187\/respcare.03920","volume":"60","author":"A Lu","year":"2015","unstructured":"Lu A, Wang C, Zhang X, Wang L, Qian L (2015) Lactate Dehydrogenase as a Biomarker for Prediction of Refractory Mycoplasma pneumoniae Pneumonia in Children. Respir Care 60(10):1469\u20131475","journal-title":"Respir Care"},{"issue":"6","key":"5519_CR58","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s10156-011-0265-7","volume":"17","author":"T Oishi","year":"2011","unstructured":"Oishi T, Narita M, Matsui K, Shirai T, Matsuo M, Negishi J, Kaneko T, Tsukano S, Taguchi T, Uchiyama M (2011) Clinical implications of interleukin-18 levels in pediatric patients with Mycoplasma pneumoniae pneumonia. J Infect Chemother 17(6):803\u2013806","journal-title":"J Infect Chemother"},{"issue":"4","key":"5519_CR59","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/ppul.22752","volume":"49","author":"Z Luo","year":"2014","unstructured":"Luo Z, Luo J, Liu E, Xu X, Liu Y, Zeng F, Li S, Fu Z (2014) Effects of prednisolone on refractory mycoplasma pneumoniae pneumonia in children. Pediatr Pulmonol 49(4):377\u2013380","journal-title":"Pediatr Pulmonol"},{"issue":"11","key":"5519_CR60","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1002\/ppul.21481","volume":"46","author":"A Lu","year":"2011","unstructured":"Lu A, Wang L, Zhang X, Zhang M (2011) Combined treatment for child refractory Mycoplasma pneumoniae pneumonia with ciprofloxacin and glucocorticoid. Pediatr Pulmonol 46(11):1093\u20131097","journal-title":"Pediatr Pulmonol"},{"issue":"3","key":"5519_CR61","first-page":"172","volume":"52","author":"L Chen","year":"2014","unstructured":"Chen L, Liu J, Zhao S, Yang Y, Wu J (2014) Clinical features and treatment of refractory Mycoplasma pneumoniae pneumonia unresponded to conventional dose methylprednisolone in children [in Chinese]. Zhonghua Er Ke Za Zhi 52(3):172\u2013176","journal-title":"Zhonghua Er Ke Za Zhi"},{"key":"5519_CR62","doi-asserted-by":"crossref","first-page":"39929","DOI":"10.1038\/srep39929","volume":"6","author":"Y Yan","year":"2016","unstructured":"Yan Y, Wei Y, Jiang W, Hao C (2016) The clinical characteristics of corticosteroid-resistant refractory Mycoplasma pneumoniae pneumonia in children. Sci Rep 6:39929","journal-title":"Sci Rep"},{"issue":"5","key":"5519_CR63","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/ppul.22650","volume":"48","author":"Y Shen","year":"2013","unstructured":"Shen Y, Zhang J, Hu Y, Shen K (2013) Combination therapy with immune-modulators and moxifloxacin on fulminant macrolide-resistant Mycoplasma pneumoniae infection: a case report. Pediatr Pulmonol 48(5):519\u2013522","journal-title":"Pediatr Pulmonol"},{"issue":"11","key":"5519_CR64","doi-asserted-by":"crossref","first-page":"e238","DOI":"10.1111\/j.1651-2227.2011.02342.x","volume":"100","author":"S Bressan","year":"2011","unstructured":"Bressan S, Mion T, Andreola B, Bisogno G, Da Dalt L (2011) Severe Mycoplasma pneumoniae-associated mucositis treated with immunoglobulins. Acta Paediatr 100(11):e238\u2013e240","journal-title":"Acta Paediatr"},{"issue":"5","key":"5519_CR65","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.pediatrneurol.2008.01.003","volume":"38","author":"A Attilakos","year":"2008","unstructured":"Attilakos A, Palaiologou P, Lagona E, Voutsioti A, Dinopoulos A (2008) Mycoplasma pneumoniae encephalopathy: recovery after intravenous immunoglobulin. Pediatr Neurol 38(5):357\u2013359","journal-title":"Pediatr Neurol"},{"issue":"2","key":"5519_CR66","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1046\/j.1365-3148.2002.00360.x","volume":"12","author":"I Krause","year":"2002","unstructured":"Krause I, Wu R, Sherer Y, Patanik M, Peter JB, Shoenfeld Y (2002) In vitro antiviral and antibacterial activity of commercial intravenous immunoglobulin preparations\u2013a potential role for adjuvant intravenous immunoglobulin therapy in infectious diseases. Transfus Med 12(2):133\u2013139","journal-title":"Transfus Med"},{"issue":"10","key":"5519_CR67","first-page":"CD009175","volume":"10","author":"K Wang","year":"2012","unstructured":"Wang K, Gill P, Perera R, Thomson A, Mant D, Harnden A (2012) Clinical symptoms and signs for the diagnosis of Mycoplasma pneumoniae in children and adolescents with community-acquired pneumonia. Cochrane Database Syst Rev 10(10):CD009175","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"5519_CR68","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1001\/archpedi.156.10.1005","volume":"156","author":"JE Fischer","year":"2002","unstructured":"Fischer JE, Steiner F, Zucol F, Berger C, Martignon L, Bossart W, Altwegg M, Nadal D (2002) Use of simple heuristics to target macrolide prescription in children with community-acquired pneumonia. Arch Pediatr Adolesc Med 156(10):1005\u20131008","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"1","key":"5519_CR69","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/14787210.2018.1414599","volume":"16","author":"H Lee","year":"2018","unstructured":"Lee H, Yun KW, Lee HJ, Choi EH (2018) Antimicrobial therapy of macrolide-resistant Mycoplasma pneumoniae pneumonia in children. Expert Rev Anti Infect Ther 16(1):23\u201334","journal-title":"Expert Rev Anti Infect Ther"}],"container-title":["European Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-024-05519-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00431-024-05519-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-024-05519-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T11:10:42Z","timestamp":1718968242000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00431-024-05519-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,18]]},"references-count":69,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["5519"],"URL":"https:\/\/doi.org\/10.1007\/s00431-024-05519-1","relation":{},"ISSN":["1432-1076"],"issn-type":[{"value":"1432-1076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,18]]},"assertion":[{"value":"31 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}